Fmr LLC Increases Holdings in uniQure (NASDAQ:QURE)

Fmr LLC increased its stake in shares of uniQure (NASDAQ:QURE) by 8,056.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 350,572 shares of the biotechnology company’s stock after buying an additional 346,274 shares during the quarter. Fmr LLC’s holdings in uniQure were worth $1,728,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares in the last quarter. Atria Investments Inc purchased a new position in uniQure during the third quarter worth approximately $53,000. Vanguard Personalized Indexing Management LLC lifted its position in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in uniQure during the third quarter worth approximately $69,000. Finally, Total Clarity Wealth Management Inc. purchased a new position in uniQure during the second quarter worth approximately $74,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.74% of the company’s stock.

uniQure Stock Up 2.3 %

Shares of NASDAQ QURE opened at $15.40 on Monday. uniQure has a twelve month low of $3.73 and a twelve month high of $17.39. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a fifty day simple moving average of $7.04 and a 200-day simple moving average of $6.37.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. As a group, sell-side analysts expect that uniQure will post -3.82 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on QURE. The Goldman Sachs Group lifted their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Royal Bank of Canada lifted their target price on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of uniQure in a research report on Tuesday, December 10th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average target price of $32.14.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.